Highest-materiality recent filing
Charlotte's Web co-founder Jared Stanley resigns from board to focus on DeFloria Phase 2 drug
Co-founder Jared Stanley resigned from Board on June 3, 2026 to become CEO of DeFloria, advancing its FDA Phase 2 botanical drug for autism irritability.
BAT converts C$75M debenture at C$0.94, invests US$10M, now owns 40.6% of Charlotte's Web
BAT invested US$10M (C$13.9M) for 14.66M common shares at C$0.94 each via private placement.
Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment
Appointed James Jeffery Raborn (EVP Law at Reynolds American/BAT) to board as BAT designee, effective May 28, 2026.
Revenue $11.2M vs $12.3M in Q1 2025; net loss includes $8.9M non-cash fair value charge on BAT convertible debenture.
BAT invests US$10M, converts C$75M debenture into ~40.8% stake in Charlotte's Web
BAT to purchase up to 14.76M common shares for US$10M (~C$13.9M) at minimum C$0.94/share.
BAT converts $65M debenture to equity, invests $10M; Charlotte's Web debt-free
Conversion of C$75.3M principal plus C$14.2M accrued interest into ~95M shares at C$0.94 per share.
Q4 2025 revenue $13.3M, up 4.7% YoY; net loss $11.5M ($0.07 loss per share).
Charlotte's Web Q3 revenue $11.5M (-8.6% YoY); net loss $5.9M; targets $9M cost savings in 2026
Revenue $11.5M vs $12.6M in Q3 2024; gross margin 38.9% (down from 53%) due to $0.5M B2B chargeback reserve and in-house manufacturing ramp.
Charlotte's Web appoints Borgia Walker to board, replacing Jonathan Atwood
Director Jonathan Atwood resigned effective October 1, 2025.
Director Jonathan Atwood resigns from Charlotte's Web board effective Oct 1, 2025
Jonathan Atwood notified the Company of his resignation from the Board of Directors on September 16, 2025.
Charlotte's Web Holdings corrects auditor appointment to PKF O'Connor Davies LLP
Amendment corrects previous 8-K: auditor appointed is PKF O'Connor Davies LLP, not Ernst & Young LLP.
Charlotte's Web Q2 revenue up 4.2% YoY to $12.8M; net loss narrows to $6.3M
Revenue $12.8M, +4.2% YoY; net loss $6.3M (-$0.04/share) vs $11.0M loss (-$0.07) in Q2 2024.
Stephen Rogers departs as SVP-GC & Corporate Secretary; Mindy Garrison replaces
Stephen Rogers, SVP-General Counsel and Corporate Secretary, departed on July 31, 2025.
Charlotte's Web lends $750,000 to joint venture DeFloria at 13.25% interest
Principal $750,000 payable in 5 monthly tranches; first $375,000 upon execution, then $93,750 each starting Aug 1, 2025.
Charlotte's Web shareholders approve all 6 director nominees and auditor appointment
Total votes cast: 58,493,957 (36.87% of outstanding voting shares).
Revenue $12.3M +1.1% YoY (first growth since Q2 2021); SG&A down 24.2%.
Charlotte's Web Q4 2024 revenue $12.7M; positive Adj. EBITDA $0.3M; full-year loss narrows
Q4 revenue $12.7M (down 20% YoY) but sequentially up from $12.6M in Q3 2024.
Charlotte's Web minority-interest DeFloria gets FDA clearance for Phase 2 autism trial
FDA cleared DeFloria's IND to proceed with Phase 2 trial of AJA001 Oral Solution for autism spectrum disorder symptoms.
Charlotte's Web PAO resigns; CFO Lind assumes PAO role effective immediately
Sarah Cambridge resigns as Principal Accounting Officer, effective Jan 31, 2025.
Charlotte's Web Q3 revenue $12.6M (-12% YoY); net loss narrows to $5.8M
Revenue $12.6M vs $14.3M YoY; net loss $5.8M ($0.04/sh) compared to $15.2M ($0.10) in Q3 2023.
Charlotte's Web enters $100K retention agreement with CFO Erika Lind
$100K aggregate retention payment to CFO, payable in four equal quarterly installments beginning Q1 2025.
California's Office of Administrative Law approved emergency regulations effective Sep 23, 2024, restricting manufacture/distribution/sale of many full-spectrum hemp CBD products.
Charlotte's Web dismisses EY as auditor, appoints PKF O'Connor Davies
Audit Committee approved appointment of PKF O'Connor Davies LLP as new independent auditor, subject to client acceptance procedures.
Charlotte's Web Q2 revenue $12.3M, net loss $11.0M; cuts costs, launches new e-commerce platform
Revenue $12.3M, down 23% YoY; net loss $11.0M ($0.07/sh) vs income $2.8M in Q2 2023.
Charlotte's Web appoints Erika Lind as CFO; Jessica Saxton departs June 28
Erika Lind appointed CFO effective June 29, 2024; joined company in 2023 as VP of FP&A and Treasury.
Charlotte's Web CCO Jared Stanley resigns, joins board; new director Maureen Usifer elected
Jared Stanley stepped down as Chief Commercial Officer effective June 13, 2024; will consult at $5,769.23 bi-weekly plus expenses.
Charlotte's Web Q1 revenue falls 29% to $12.1M; net loss widens to $9.7M
Revenue $12.1M (down 29% YoY); net loss $9.7M vs $2.9M loss in Q1 2023.
Three directors (John Held, Thomas Lardieri, Alicia Morga) will not stand for re-election at June 13, 2024 AGM; no disagreement cited.
Charlotte's Web Q4 net loss $8.5M; FY revenue down 14.8% to $63.2M, launches True North turnaround
Q4 2023 revenue $15.9M (-16% YoY); gross profit $8.9M (56% margin); net loss $8.5M ($0.06/share).
Charlotte's Web enters Master Services Agreement with DeFloria LLC for joint venture services
DeFloria LLC formed April 2023 with AJNA BioSciences and BAT subsidiary; Charlotte's Web and AJNA each hold 50% voting common units.
Charlotte's Web extends MLB deal to 2027 ($23M fee), adds ex-Ben & Jerry's CEO to board
MLB partnership extended to Dec 31, 2027 with aggregate rights fee of $23M for the remainder of the term.
Charlotte's Web accelerates vesting of 542,426 RSUs for CFO Saxton and two other officers
CFO Jessica Saxton received accelerated vesting of 401,786 RSUs originally scheduled through April 2026.
Charlotte's Web extends $1M founder loan maturity to Nov 2024
Second amendment to $1M promissory note extends maturity from Nov 13, 2023 to Nov 13, 2024.
Charlotte's Web Q3 revenue falls 16% to $14.3M; net loss widens to $15.2M; new CEO appointed
Q3 revenue $14.3M, down from $17.0M YoY; net loss $15.2M ($0.10/share) vs $7.6M ($0.05).
Charlotte's Web appoints Angela McElwee, ex-CEO of Gaia Herbs, to board
Angela McElwee appointed to Board of Directors effective October 11, 2023.
Charlotte's Web appoints Bill Morachnick as CEO; Tortoroli departs
William Morachnick named CEO and non-independent director effective Sept 13, 2023, replacing Jacques Tortoroli.
Charlotte's Web appoints Sarah Cambridge as CAO effective Aug 28, 2023
Sarah Cambridge appointed Chief Accounting Officer; she joined the company in July 2022 as Corporate Controller.
Revenue $16.0M vs $18.9M YoY (-15%); gross margin improved to 55.7% from 49.4%.
Charlotte's Web extends name and likeness license with Stanley Brothers to Dec 31, 2023
Extended Name and Likeness License Agreement with Leeland & Sig LLC (Stanley Brothers Brand Company) from June 30 to December 31, 2023.
Four Charlotte's Web directors receive only ~33% support; offer resignations per policy
Directors Held, Lardieri, Morga, Tortoroli each received ≈33% votes for, ≈67% withheld at June 15 AGM.
Joel and Jesse Stanley demanded replacement of majority of board within 48 hours; board refuses.
Charlotte's Web Q1 revenue falls 12.1% to $17M; net loss narrows to $2.9M
Revenue $17.0M, down 12.1% YoY from $19.4M; driven by lower oil tincture volume and mix shift to gummies.
Charlotte's Web forms JV with BAT and AJNA to develop FDA-approved hemp botanical drug
BAT invests $10M for 20% preferred equity; Charlotte's Web and AJNA each hold 40% voting common.
Charlotte's Web amends CFO Jessica Saxton's compensation package
Relocation reimbursement raised from $40,000 to $45,000.
Charlotte's Web Q4 2022 revenue down 23.8% to $18.9M; net loss $35.2M
Full-year 2022 revenue $74.1M (down 22.8% YoY); net loss $59.3M vs $137.7M in 2021.
Charlotte's Web appoints Jonathan Atwood to board of directors
Atwood appointed effective March 14, 2023; term expires at 2023 annual meeting.
Charlotte's Web extends name and likeness license with Stanley Brothers to June 30, 2023
License agreement term extended to June 30, 2023 via Fifth Amending Agreement effective Feb 17, 2023.
Charlotte's Web names Jessica Saxton CFO effective Jan 1, 2023; Greg Gould departs Dec 31
Jessica Saxton appointed CFO effective Jan 1, 2023, succeeding Greg Gould, who departs Dec 31, 2022 without disagreement.
Charlotte's Web appoints Alicia Morga to Board; Jean Birch retires
Alicia Morga appointed to Board of Directors effective Dec 6, 2022, replacing Jean Birch who immediately retired.
Investment of US$56.8M (C$75.3M) from BT DE Investments, wholly owned by British American Tobacco (NYSE: BTI).
On June 3, 2026, Mr. Jared Stanley notified Charlotte’s Web Holdings, Inc. (the “Company”) of his intention to resign from his position as a member of the Board of Directors of the Company (and any committees upon which he sits) effective as of June 3, 2026.
Effective May 28, 2026 (the “Effective Date”), the board of directors of Charlotte’s Web Holdings, Inc. (the “Company”), appoint James Jeffery Raborn to the Company’s board of directors
Ms. Erika Lind, the Company’s Chief Financial Officer, will assume the role of Principal Accounting Officer effective immediately.
On January 15, 2025, Sarah Cambridge submitted her resignation as Principal Accounting Officer of the Company, effective January 31, 2025.
On June 18, 2024, Charlotte’s Web Holdings, Inc. (the “Company”) announced the appointment of Erika Lind, age 52, as the Company’s Chief Financial Officer effective June 29, 2024.
Jessica Saxton, who provided notice to the Company on June 17, 2024, that she will depart the Company effective June 28, 2024.
On June 14, 2024, Charlotte’s Web Holdings, Inc. (the “Company”) announced that Jared Stanley, its Chief Commercial Officer, will leave the employment of the Company effective June 13, 2024.
three current members of the Company’s Board of Directors, John Held, Thomas Lardieri, and Alicia Morga, will not stand for re-election at the Company’s Annual General and Special Meeting scheduled for June 13, 2024.
three current members of the Company’s Board of Directors, John Held, Thomas Lardieri, and Alicia Morga, will not stand for re-election at the Company’s Annual General and Special Meeting scheduled for June 13, 2024.
three current members of the Company’s Board of Directors, John Held, Thomas Lardieri, and Alicia Morga, will not stand for re-election at the Company’s Annual General and Special Meeting scheduled for June 13, 2024.
Effective February 6, 2024 (the “Effective Date”), the Board of Directors of the Company, appointed Matthew McCarthy to the Company’s Board of Directors
who notified the Company and the board of directors of her immediate retirement from the board of directors
Max materiality 0.85 · Median 0.57 · Most common event other_material